Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care and ...

The jury’s finding in favor of Guardant includes the allotment of $175.5 million in punitive damages. As Natera seeks to reverse the ruling, Guardant was much more enthusiastic about the outcome.

A U.S. jury awarded Guardant Health $292.5 million after ruling that a rival engaged in false advertising and unfair competition, the company said last week. Guardant filed a lawsuit in May 2021 ...

Diagnostics company Guardant Health (NASDAQ:GH) will be reporting earnings tomorrow after market hours. Here’s what you need to know. Guardant Health beat analysts’ revenue expectations by 4.8 ...

This legal action adds to a series of disputes between the two companies. In November 2024, Guardant won a $292.5 million verdict against Natera for false advertising, wherein Natera was found to have ...

Genomics company Illumina and cancer-test maker Guardant Health have settled a lawsuit in Delaware federal court that accused Guardant of stealing Illumina's trade secrets, according to a press ...

The jury awarded Guardant $292.5 million, including $175.5 million in punitive damages, which the company described as one of the largest false advertising verdicts in history. The jury also ...

With a stock down nearly 50% over the last 52 weeks, investors in Guardant Health (GH-2.49%) haven't had a lot to cheer about this year. The last couple of days, however, may be changing that.

If approved, Guardant Health’s liquid biopsy is likely to be a strong new addition to colorectal cancer screening tools, particularly for patients who currently choose not to get screened.

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Guardant Health wasn’t one of them. The 10 stocks that made ...

Shares of Guardant Health jumped 7% on Monday, after the Food and Drug Administration approved the company’s blood test to screen for colon cancer, a new testing method the company said is ...

With shares of Guardant currently trading around the $51 handle, the purchase of the $47 regular December put option, the sale of two $45 put options, and then the purchase of one corresponding ...